NeuroStar Advanced Therapy should not be used with patients who have non-removable conductive metal in or near the head. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient). These events are transient they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. The most common side effect is pain or discomfort at or near the treatment site. A doctor can help decide if NeuroStar Advanced Therapy is right for you. NeuroStar Advanced Therapy is only available by prescription. The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). NeuroStar Advanced Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. CGI-S represents the scale used to define response and remission. Standard of care also included medications. ***Patients received more than one course of treatment and were treated with standard of care. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. ![]() **Outcomes Registry data was published by Sackeim HA, et al. *Free consultations are determined by providers and may not be guaranteed. She is a member of the American Psychiatric Association (APA) Council on Research and has published extensively on TMS and other treatments for depression. ![]() She is a faculty member of several national TMS training courses and serves on the Board of Directors of the Clinical TMS Society. Carpenter was engaged in TMS research prior to the first FDA clearance in 2008, and has remained active as a TMS clinician and researcher since then. She is the founding Director of the Butler Hospital TMS Clinic and Neuromodulation Research Facility and co-author of several published TMS Clinical practice guidelines. ![]() Carpenter has also conducted a number of randomized clinical trials sponsored by industry and NIH, investigating investigational drugs and devices for treating depression, including esketamine, Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS). She has continued her path since then as a physician-researcher investigating the neurobiology of, and new treatments for, major depression and other mood and anxiety disorders. She did an internship in internal medicine, psychiatry residency, and research fellowship at Yale, then joined the faculty at Brown in 1997. She completed her undergraduate degree at the University of Michigan and medical school at the University of Pennsylvania. Carpenter, MD is a Professor of Psychiatry in the Alpert Medical School of Brown University and Chief of the Mood Disorders Program at Butler Hospital.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |